|Application ||WB, E|
|Other Accession||AAM77366, 9966|
|Calculated MW||28087 Da|
|Application Notes||TL1A antibody can be used for detection of TL1A by Western blot at 2 μg/mL.|
|Other Names||TL1A Antibody: TL1, TL1A, VEGI, VEGI192A, TL1, Tumor necrosis factor ligand superfamily member 15, TNF ligand-related molecule 1, tumor necrosis factor (ligand) superfamily, member 15|
|Target/Specificity||TL1A antibody was raised against recombinant human TL1A.|
|Reconstitution & Storage||TL1A antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||TL1A Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis.|
|Cellular Location||Membrane; Single-pass type II membrane protein|
|Tissue Location||Specifically expressed in endothelial cells. Detected in monocytes, placenta, lung, liver, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine and colon|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TL1A Antibody: Members in the TNF and its receptor superfamilies regulate immune responses and induce apoptosis. DR3 (also termed Wsl-1, Apo-3, TRAMP, and LARD) is preferentially expressed by T lymphocytes and upregulated during T cell activation. The ligand for DR3 was recently identified and designated TL1A. TL1A also binds decoy receptor DcR3/TR6, which is expressed in several lung and colon carcinomas and in some normal tissues. TL1A induces apoptosis and NF-κB activation in DR3 expressing cells, which is antagonized by DcR3. TL1A is upregulated by proinflammatory cytokines TNF and IL-1. TL1A is a longer variant of TL1 (also called VEGI).
Chinnayan AM, O’Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274:990-2.
Kitson J, Raven T, Jiang YP, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996; 384:372-5.
Screaton GR, Xu XN, Olsen AL, et al. LARD: a new lymphoid-specific death domain containing receptor regulated by pre-mRNA splicing. Proc. Natl. Acad. Sci. USA 1997; 94:4615-9.
Bodmer JL, Burns K, Schneider P. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). Immunity 1997; 6:79-88.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.